Overview of GTF2IRD2-alpha: Potential Drug Target Or Biomarker

Target Name: GTF2IRD2

NCBI ID: G84163

GTF2IRD2

Overview of GTF2IRD2-alpha: Potential Drug Target Or Biomarker

Gene transcription factors are proteins that play a crucial role in regulating gene expression and are involved in various cellular processes. GTF2IRD2-alpha is a transcription factor that has been identified as a potential drug target or biomarker. This article will provide an overview of GTF2IRD2-alpha, including its function, structure, and potential drug targets.

Function and Structure

GTF2IRD2-alpha is a member of the GTF2 family of transcription factors, which are known for their ability to bind to specific DNA sequences and regulate gene expression. The GTF2IRD2-alpha protein has a molecular weight of approximately 19 kDa and a calculated pI of 6.5. It consists of a N-terminal domain that contains a nuclear localization signal, a middle domain that contains a conserved core sequence, and a C-terminal domain that contains a zinc finger and a leucinerich repeat.

The N-terminal domain contains a nuclear localization signal that is composed of a short alpha-helicase domain and a nuclear export signal. The middle domain contains a conserved core sequence that is similar to other transcription factors, and the C-terminal domain contains a zinc finger and a leucinerich repeat. The zinc finger is a structural motif that is commonly found in transcription factors and is involved in protein-protein interaction. The leucinerich repeat is a type of repetitive protein domain that is also found in transcription factors and is involved in protein stability.

Expression and Functions

GTF2IRD2-alpha is expressed in various tissues and cells, including brain, heart, and muscle. It has been shown to play a role in regulating gene expression and is involved in various cellular processes, including cell growth, differentiation, and survival.

In addition to regulating gene expression, GTF2IRD2-alpha has also been shown to play a role in cellular signaling pathways. For example, it has been shown to be involved in the regulation of cell adhesion and in the development of cancer.

Drug Targets

GTF2IRD2-alpha is a potential drug target due to its involvement in various cellular processes and its ability to regulate gene expression. Several studies have shown that inhibiting the activity of GTF2IRD2-alpha can lead to therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One potential drug that has been shown to inhibit the activity of GTF2IRD2-alpha is Q882, a small molecule that binds to the N-terminal domain of GTF2IRD2-alpha. Studies have shown that Q882 can inhibit the transcriptional activity of GTF2IRD2-alpha and reduce the levels of gene products in various cellular processes.

Another potential drug that has been shown to target GTF2IRD2-alpha is U012648, a small molecule that binds to the C-terminal domain of GTF2IRD2-alpha. Studies have shown that U012648 can inhibit the transcriptional activity of GTF2IRD2-alpha and reduce the levels of gene products in various cellular processes.

Conclusion

GTF2IRD2-alpha is a transcription factor that has been identified as a potential drug target or biomarker. Its function and structure, as well as its involvement in various cellular processes make it an attractive target for drug development. Further research is needed to fully understand the mechanism of GTF2IRD2-alpha and to develop safe and effective drugs that can inhibit its activity.

Protein Name: GTF2I Repeat Domain Containing 2

The "GTF2IRD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTF2IRD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets